Drugs / Metronidazole
Metronidazole
also known as
Flagyl · MTZ · metronidazol · MET · Metrogel · METRO · Metronidazole Hydrochloride · Metronidazole-Flagyl · +22 more
Regulatory milestones approvals, filings & regulatory actions · 4 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansion | US (FDA) | NUVESSA | — | 2018-08-03 | fda.gov ↗ |
| Label expansion | US (FDA) | METROGEL-VAGINAL | — | 1997-05-16 | fda.gov ↗ |
| Label expansion | US (FDA) | FLAGYL | — | 1988-02-10 | fda.gov ↗ |
| Approved | US (FDA) | FLAGYL | — | 1963-07-18 | fda.gov ↗ |
Trials 318 · started per year
today
US approved 1963
1
1
1
3
3
5
6
4
10
7
7
9
13
19
14
16
15
20
13
18
17
14
13
18
13
13
18
17
9
19621963196419651966196719681969197019711972197319741975197619771978197919801981198219831984198519861987198819891990199119921993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023202420252026202720282029
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 09 trials | ||||||
| Phase 0 | NCT07592416 | Aug 2023 → Jan 2026 | periodontitis | University of Sao Paulo | Completed | No outcome recorded |
| Phase 0 | NCT04977882 | Oct 2020 → Aug 2022 | colon carcinoma | University of Rome Tor Vergata | Completed | No outcome recorded |
| Phase 0 | NCT03271983 | Apr → Oct 2019 | — | University of Maryland, Baltimore | Completed | No outcome recorded |
| Phase 0 | NCT02447224 | Mar → Oct 2015 | appendicitis | Olive View-UCLA Education & Research Institute | Completed | No outcome recorded |
| Phase 0 | NCT02185456 | Sep 2014 → Jan 2016 | bacterial vaginosis | Wayne State University | Unknown | No outcome recorded |
| Phase 0 | NCT02142543 | Mar → Dec 2012 | aphthous stomatitis | Texas A&M University | Completed | No outcome recorded |
| Phase 0 | NCT00881907 | Mar 2010 → Mar 2014 | dental pulp necrosis | The University of Texas Health Science Center at San Antonio | Completed | No outcome recorded |
| Phase 0 | NCT00881491 | Apr 2009 → Jan 2015 | dental pulp necrosis | The University of Texas Health Science Center at San Antonio | Completed | No outcome recorded |
| Phase 0 | NCT00503542 | Feb 2007 → Feb 2008 | vaginitis | Agency for Healthcare Research and Quality (AHRQ) | Completed | No outcome recorded |
| Phase 122 trials · 2 met primary · 1 missed | ||||||
| Phase 1 | NCT06925490 | Jun 2025 → Sep 2026 overdue | pulpitis | Cairo University | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07251127 | May → Jun 2025 | Clostridium difficile colitis | Gateway Pharmaceutical LLC | Completed | No outcome recorded |
| Phase 1 | NCT06806995 | Jan → Feb 2025 | pseudohypoparathyroidism type 1A | Wockhardt | Completed | No outcome recorded |
| Phase 1 | NCT06478940 | Aug 2024 → Aug 2025 | dental pulp disorder | Cairo University | Unknown | No outcome recorded |
| Phase 1 | NCT05724628 | Oct → Nov 2023 | appendicitis | University of Texas Southwestern Medical Center | Withdrawn | No outcome recorded |
| Phase 1 | NCT05861310 | May → Jul 2023 | rosacea | Indonesia University | Unknown | No outcome recorded |
| Phase 1 | NCT03332732 | Oct → Dec 2017 | bacterial infectious disease | Venatorx Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03187106 | Aug 2017 → Jul 2023 | — | The University of Texas Medical Branch, Galveston | Completed | Missed primary |
| Phase 1 | NCT02527941 | Aug → Nov 2015 | HIV infectious disease, bacterial vaginosis | University of Toronto | Completed | No outcome recorded |
| Phase 1 | NCT02402283 | May 2015 | — | Verisfield UK Ltd. Greek Branch | Completed | No outcome recorded |
| Phase 1 | NCT01976065 | Sep 2014 → Sep 2018 | dental pulp necrosis | Kenneth Hargreaves | Completed | No outcome recorded |
| Phase 1 | NCT02146209 | Jun 2014 | bacterial infectious disease | Verisfield UK Ltd. Greek Branch | Completed | No outcome recorded |
| Phase 1 | NCT01813162 | Dec 2013 → Dec 2014 | — | CONRAD | Completed | No outcome recorded |
| Phase 1 | NCT01418365 | Aug → Oct 2011 | — | Shire | Completed | Met primary |
| Phase 1 | NCT01407016 | Aug → Sep 2011 | infectious disease | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT01513863 | Aug 2011 → Jun 2012 | rosacea | Sun Pharmaceutical Industries, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01222585 | Jan → Nov 2011 | infectious disease, necrotizing enterocolitis | Michael Cohen-Wolkowiez | Completed | No outcome recorded |
| Phase 1 | NCT01085760 | Feb 2010 → Nov 2011 | primary sclerosing cholangitis | Mayo Clinic | Completed | Met primary |
| Phase 1 | NCT01059890 | Sep 2009 → Jun 2013 | bacterial infectious disease, brain injury | Poitiers University Hospital | Completed | No outcome recorded |
| Phase 1 | NCT00774969 | Oct 2007 → Apr 2008 | perianal Crohn disease | S.L.A. Pharma AG | Completed | No outcome recorded |
| Phase 1 | NCT01380522 | Aug → Sep 2002 | — | Par Pharmaceutical, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01380509 | Aug → Sep 2002 | — | Par Pharmaceutical, Inc. | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT06126731 | Nov 2023 → Jun 2026 overdue | castration-resistant prostate carcinoma | Institute of Cancer Research, United Kingdom | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04979832 | Sep 2021 → Dec 2023 | pouchitis | Zealand University Hospital | Unknown | No outcome recorded |
| Phase 245 trials · 2 met primary · 1 missed | ||||||
| Phase 2 | NCT07451171 | Apr → Aug 2026 overdue | small intestinal bacterial overgrowth | University of Virginia | Recruiting | No outcome recorded |
| Phase 2 | NCT07481955 | Mar 2026 → Mar 2027 expected | bacterial vaginosis | Freya Biosciences ApS | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07146217 | Aug 2025 → Jul 2026 overdue | bacterial infectious disease | Saptalis Pharmaceuticals LLC | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06627270 | Mar 2025 → Oct 2026 expected | oral cavity squamous cell carcinoma | Case Comprehensive Cancer Center | Recruiting | No outcome recorded |
| Phase 2 | NCT06728072 | Mar 2025 → Jul 2035 expected | colorectal cancer | Virginia Commonwealth University | Recruiting | No outcome recorded |
| Phase 2 | NCT06616597 | Feb 2025 → Mar 2031 expected | metastatic prostate carcinoma, prostate adenocarcinoma | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Recruiting | No outcome recorded |
| Phase 2 | NCT06798415 | Feb → May 2025 overdue | cutaneous leishmaniasis | Hayder Adnan Fawzi | Recruiting | No outcome recorded |
| Phase 2 | NCT06793137 | Jul 2024 → Oct 2025 overdue | rectum adenocarcinoma | AC Camargo Cancer Center | Recruiting | No outcome recorded |
| Phase 2 | NCT06569368 | Jul 2024 → Oct 2027 expected | rectum adenocarcinoma | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
| Phase 2 | NCT07264842 | Jun 2024 → Apr 2026 overdue | dental pulp necrosis | Dow University of Health Sciences | Recruiting | No outcome recorded |
| Phase 2 | NCT06356597 | Apr 2024 → Dec 2026 expected | colorectal cancer | Jing-yuan Fang, MD, Ph. D | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05748145 | Sep 2023 → Dec 2026 expected | colorectal cancer | Oncology Institute of Southern Switzerland | Recruiting | No outcome recorded |
| Phase 2 | NCT05462496 | Mar 2023 → Aug 2027 expected | malignant pancreatic neoplasm | Icahn School of Medicine at Mount Sinai | Recruiting | No outcome recorded |
| Phase 2 | NCT05774964 | Mar 2023 → Mar 2025 | — | Liaoning Cancer Hospital & Institute | Unknown | No outcome recorded |
| Phase 2 | NCT05720559 | Mar 2023 → Mar 2026 overdue | — | Liaoning Cancer Hospital & Institute | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT04955574 | Jan 2023 → Jan 2024 | endometriosis, infertility disorder | McMaster University | Withdrawn | No outcome recorded |
| Phase 2 | NCT04723069 | Sep 2021 → Mar 2022 | pelvic inflammatory disease | University of Karachi | Completed | Met primary |
| Phase 2 | NCT04186247 | Aug 2021 → Dec 2023 | Crohn disease | University of North Carolina, Chapel Hill | Terminated | No outcome recorded |
| Phase 2 | NCT05205993 | Jan 2021 → Jan 2024 | chronic endometritis | Genesis Athens Clinic | Unknown | No outcome recorded |
| Phase 2 | NCT04312360 | Jan 2020 → Apr 2022 | colon adenoma, malignant colon neoplasm | Zealand University Hospital | Completed | No outcome recorded |
| Phase 2 | NCT03794765 | Apr 2019 → Mar 2020 | ulcerative colitis | Post Graduate Institute of Medical Education and Research, Chandigarh | Completed | Missed primary |
| Phase 2 | NCT03992144 | Oct 2018 → Jan 2019 | alveolar periostitis | Dow University of Health Sciences | Completed | No outcome recorded |
| Phase 2 | NCT03217136 | Apr 2018 → Mar 2020 | — | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 2 | NCT03435900 | Feb → Jul 2018 | appendicitis | Herlev Hospital | Completed | Met primary |
| Phase 2 | NCT02682485 | Mar 2017 | intestinal perforation, rectal cancer | University of Chicago | Withdrawn | No outcome recorded Stop: Business |
| Phase 2 | NCT04447625 | Mar 2017 → Feb 2019 | chronic endometritis | Genesis Athens Clinic | Completed | No outcome recorded |
| Phase 2 | NCT03046758 | Feb → Dec 2017 | appendicitis | Herlev Hospital | Completed | No outcome recorded |
| Phase 2 | NCT02761005 | May 2016 → Mar 2018 | Helicobacter pylori infectious disease | Hamamatsu University | Unknown | No outcome recorded |
| Phase 2 | NCT02746276 | Apr → Sep 2016 | protein-energy malnutrition | University of Oxford | Unknown | No outcome recorded |
| Phase 2 | NCT02475733 | Aug 2015 → Jun 2017 | — | Pfizer | Completed | No outcome recorded |
| Phase 2 | NCT02388581 | Dec 2014 → Dec 2017 | gastric diffuse large B-cell lymphoma | National Health Research Institutes, Taiwan | Unknown | No outcome recorded |
| Phase 2 | NCT02366884 | Jul 2011 → Dec 2022 | neoplasm | Dr. Frank Arguello Cancer Clinic | Unknown | No outcome recorded |
| Phase 2 | NCT01279252 | Jul 2011 → Jan 2015 | chronic lymphocytic leukemia/small lymphocytic lymphoma | King's College Hospital NHS Trust | Completed | No outcome recorded |
| Phase 2 | NCT01230814 | Apr 2011 → Aug 2013 | bacterial vaginosis, candidiasis, trichomoniasis | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | Mixed |
| Phase 2 | NCT00752219 | Mar → Nov 2009 | — | Pfizer | Completed | No outcome recorded |
| Phase 2 | NCT00642473 | Feb 2008 → Mar 2009 | non-small cell lung carcinoma | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 2 | NCT00425113 | Dec 2006 → Oct 2012 | multidrug-resistant tuberculosis | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 2 | NCT00257699 | May 2006 → Jul 2008 | Crohn's colitis | Mount Sinai Hospital, Canada | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT00469430 | May 2006 → Sep 2007 | appendicitis | Göteborg University | Completed | No outcome recorded |
| Phase 2 | NCT00249782 | Nov 2005 → May 2006 | rosacea | Allergan | Completed | No outcome recorded |
| Phase 2 | NCT00484250 | Sep 2005 → May 2006 | lichen planus, oral | Mashhad University of Medical Sciences | Completed | No outcome recorded |
| Phase 2 | NCT00417872 | Jan 2004 → Sep 2005 | Clostridium difficile colitis | Romark Laboratories L.C. | Completed | No outcome recorded |
| Phase 2 | NCT00438269 | Feb 2003 → Mar 2005 | nosocomial infection, pneumonia | Canadian Critical Care Trials Group | Completed | No outcome recorded |
| Phase 2 | NCT00003151 | Sep 1997 → Oct 1998 | lymphoma | European Organisation for Research and Treatment of Cancer - EORTC | Completed | No outcome recorded |
| Phase 2 | NCT00002682 | Aug 1995 → Oct 2001 | lymphoma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 2/37 trials | ||||||
| Phase 2/3 | NCT06153706 | Jun 2022 → Oct 2023 | periodontitis | Yasmeen Khaled | Completed | No outcome recorded |
| Phase 2/3 | NCT04319575 | Dec 2018 → Apr 2020 | suppurative periapical periodontitis | Dr. D. Y. Patil Dental College & Hospital | Unknown | No outcome recorded |
| Phase 2/3 | NCT03343366 | Jan 2018 → Jun 2020 | chronic periodontitis, type 2 diabetes mellitus | Dow University of Health Sciences | Completed | No outcome recorded |
| Phase 2/3 | NCT02642250 | Jan → Dec 2015 | chronic diarrheal disease | Shifa Ul Mulk Memorial Hospital | Completed | No outcome recorded |
| Phase 2/3 | NCT02004197 | Jan 2010 → Sep 2012 | Helicobacter pylori infectious disease | Hafiz Muhammad Asif | Completed | No outcome recorded |
| Phase 2/3 | NCT00774722 | Sep 2006 → Mar 2008 | hemorrhoid | S.L.A. Pharma AG | Completed | No outcome recorded |
| Phase 2/3 | NCT00197418 | Aug 2003 → ? | Helicobacter pylori infectious disease, duodenal ulcer, gastric ulcer, gastritis | Hamamatsu University | Unknown | No outcome recorded |
| Phase 345 trials · 7 met primary · 6 missed | ||||||
| Phase 3 | NCT06572761 | Sep 2026 → May 2030 expected | cervical incompetence | Assistance Publique - Hôpitaux de Paris | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT05821478 | May 2025 → Feb 2027 expected | hidradenitis suppurativa | Institut Pasteur | Recruiting | No outcome recorded |
| Phase 3 | NCT06387147 | Jan 2025 → Nov 2027 expected | acute intestinal ischemia | Assistance Publique - Hôpitaux de Paris | Recruiting | No outcome recorded |
| Phase 3 | NCT06131021 | Apr 2024 → Apr 2026 | periodontitis | Rutgers, The State University of New Jersey | Completed | No outcome recorded |
| Phase 3 | NCT05079802 | Dec 2021 → Dec 2023 | tooth resorption | Ain Shams University | Unknown | No outcome recorded |
| Phase 3 | NCT04927312 | Oct 2021 → Sep 2022 | — | Pfizer | Completed | Met primary |
| Phase 3 | NCT04107194 | Jan 2020 → Feb 2021 | Helicobacter pylori infectious disease | University of Bari | Unknown | No outcome recorded |
| Phase 3 | NCT03830333 | Mar 2019 → Oct 2020 | — | Merck Sharp & Dohme LLC | Completed | Met primary |
| Phase 3 | NCT03733379 | Nov 2018 → Dec 2020 | periodontitis | Belén Retamal-Valdes | Unknown | No outcome recorded |
| Phase 3 | NCT03174236 | Sep 2017 → Jan 2020 | poisoning, protein-energy malnutrition | University of Oxford | Unknown | No outcome recorded |
| Phase 3 | NCT04547764 | Jun 2017 → Dec 2018 | dental pulp disorder | King Abdulaziz University | Completed | No outcome recorded |
| Phase 3 | NCT03177629 | May 2017 → Jun 2020 | Helicobacter pylori infectious disease, autoimmune thrombocytopenic purpura | Seoul National University Hospital | Unknown | Met primary |
| Phase 3 | NCT02739997 | Apr 2016 → Jul 2017 | — | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT02557932 | Sep 2015 → Dec 2018 | Helicobacter pylori infectious disease, hereditary gastric cancer | National Cancer Center, Korea | Completed | Met primary |
| Phase 3 | NCT03148366 | Feb 2015 → Dec 2019 | Helicobacter pylori infectious disease | National Taiwan University Hospital | Completed | Missed primary |
| Phase 3 | NCT02209519 | Feb 2015 → Mar 2019 | bacterial vaginosis | University of Alabama at Birmingham | Completed | Missed primary |
| Phase 3 | NCT01832480 | Oct 2014 → Jun 2017 | trichomonal vulvovaginitis | Tulane University Health Sciences Center | Completed | No outcome recorded |
| Phase 3 | NCT02236403 | Oct 2014 → Jan 2015 | blepharitis | National University of Colombia | Completed | No outcome recorded |
| Phase 3 | NCT02713139 | Sep 2013 → Mar 2014 | vaginal discharge | Ache Laboratorios Farmaceuticos S.A. | Withdrawn | No outcome recorded |
| Phase 3 | NCT02394821 | Sep 2013 → Jul 2014 | neoplasm | University of Sao Paulo | Completed | No outcome recorded |
| Phase 3 | NCT01863407 | Apr 2013 → Nov 2014 | ileus | Beijing Bozhiyin T&S Co., Ltd. | Unknown | No outcome recorded |
| Phase 3 | NCT01726023 | Jan 2013 → Mar 2015 | — | Pfizer | Completed | Met primary |
| Phase 3 | NCT01541930 | Apr → Dec 2012 | chronic ulcer of skin | Galderma R&D | Completed | No outcome recorded |
| Phase 3 | NCT01499290 | Mar 2012 → Apr 2014 | — | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT01445678 | Dec 2011 → Oct 2013 | — | Merck & Co., Inc. | Completed | Met primary |
| Phase 3 | NCT01473836 | Nov 2011 → Oct 2012 | infectious peritonitis | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT01287728 | Jan 2011 → Jan 2016 | bacterial vaginosis | Assistance Publique Hopitaux De Marseille | Completed | No outcome recorded |
| Phase 3 | NCT01275560 | Jan 2011 → Jun 2015 | anus disorder | University Hospital, Rouen | Completed | Met primary |
| Phase 3 | NCT01061437 | Jun 2009 → Jul 2011 | Helicobacter pylori infectious disease | SWOG Cancer Research Network | Completed | Missed primary |
| Phase 3 | NCT00712413 | Aug → Dec 2008 | Helicobacter pylori infectious disease | Forest Laboratories | Withdrawn | No outcome recorded |
| Phase 3 | NCT00667368 | Jul 2008 → Dec 2014 | bacterial vaginosis | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | Missed primary |
| Phase 3 | NCT01524081 | Jul 2008 → Jul 2011 | appendicitis, intestinal obstruction, peptic ulcer perforation | The Faculty Hospital Na Bulovce | Completed | No outcome recorded |
| Phase 3 | NCT01016782 | Jan 2008 → Jul 2009 | rosacea | Fougera Pharmaceuticals Inc. | Completed | No outcome recorded |
| Phase 3 | NCT01867164 | Dec 2007 → Dec 2008 | infective vaginitis | Janssen-Cilag, S.A. | Completed | No outcome recorded |
| Phase 3 | NCT00719420 | Apr 2006 → Feb 2007 | Helicobacter pylori infectious disease | University of North Texas Health Science Center | Completed | No outcome recorded |
| Phase 3 | NCT00629135 | Nov 2005 → Aug 2011 | abscess | Hannover Medical School | Completed | No outcome recorded |
| Phase 3 | NCT00509639 | May 2005 → Feb 2008 | perianal Crohn disease | S.L.A. Pharma AG | Completed | Missed primary |
| Phase 3 | NCT00182429 | Feb 2004 → Apr 2005 | Clostridium difficile colitis | McMaster University | Completed | No outcome recorded |
| Phase 3 | NCT00313131 | Jan 2004 → May 2005 | bacterial vaginosis, candidiasis | University of Sherbrooke | Completed | No outcome recorded |
| Phase 3 | NCT00170430 | May 2003 → Dec 2006 | bacterial infectious disease, fungal infectious disease, sexually transmitted disease | University of Washington | Completed | No outcome recorded |
| Phase 3 | NCT00140764 | Jan 2003 → Mar 2005 | Trichomonas vaginitis urogenital infection, bacterial vaginosis | Johns Hopkins Bloomberg School of Public Health | Completed | No outcome recorded |
| Phase 3 | NCT00481702 | Dec 2001 → Jun 2003 | intestinal infectious disease | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT00154440 | Nov 2001 → Oct 2013 | non-Hodgkin lymphoma | Technical University Dresden | Unknown | No outcome recorded |
| Phase 3 | NCT01098448 | Sep 1999 → Dec 2004 | periodontitis | The Forsyth Institute | Completed | No outcome recorded |
| Phase 3 | NCT00021671 | ? → Nov 2004 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | Missed primary |
| Phase 4111 trials · 14 met primary · 5 missed | ||||||
| Phase 4 | NCT07704359 | Oct 2026 → Feb 2029 expected | anal fistula | University of Illinois at Chicago | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07392047 | Feb → Aug 2026 overdue | acne | Jinnah Postgraduate Medical Centre | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07445282 | May → Nov 2025 | typhoid fever | Sheikh Zayed Medical College | Completed | No outcome recorded |
| Phase 4 | NCT06261840 | May 2025 → May 2029 expected | Trichomonas vaginitis urogenital infection, bacterial vaginosis | Tulane University | Recruiting | No outcome recorded |
| Phase 4 | NCT06920147 | May 2025 → Mar 2027 expected | — | The University of Texas Health Science Center, Houston | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06561711 | Aug 2024 → Feb 2026 | Helicobacter pylori infectious disease | Shanghai Jiao Tong University School of Medicine | Completed | No outcome recorded |
| Phase 4 | NCT06561698 | Aug 2024 → Aug 2026 overdue | Helicobacter pylori infectious disease | Shanghai Jiao Tong University School of Medicine | Recruiting | No outcome recorded |
| Phase 4 | NCT06349122 | Aug 2024 → Mar 2027 expected | bacterial vaginosis | Assistance Publique Hopitaux De Marseille | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06396078 | Jul 2024 → Dec 2026 expected | preterm premature rupture of the membranes | Ohio State University | Recruiting | No outcome recorded |
| Phase 4 | NCT07312721 | Jan → Dec 2024 | Helicobacter pylori infectious disease, chronic gastritis, peptic ulcer disease | Azfar Farogh | Completed | No outcome recorded |
| Show all 111 trials opens the full record — a long page | ||||||
| Phase not applicable77 trials · 3 met primary · 7 missed | ||||||
| — | NCT07833176 | Sep 2026 → Feb 2027 expected | alveolar periostitis | Khyber Medical University Peshawar | Not yet recruiting | No outcome recorded |
| — | NCT07239739 | Jun → Nov 2026 expected | periapical periodontitis | Faiz ur rahman | Not yet recruiting | No outcome recorded |
| — | NCT06943794 | Mar 2026 → May 2030 expected | gastric cancer | Fudan University | Not yet recruiting | No outcome recorded |
| — | NCT07512648 | Mar 2026 → Apr 2028 expected | breast disorder, granulomatous mastitis | Caigang Liu | Not yet recruiting | No outcome recorded |
| — | NCT07867951 | Sep 2025 → May 2026 overdue | periapical periodontitis | College of Physicians and Surgeons Pakistan | Recruiting | No outcome recorded |
| — | NCT07429760 | Aug 2025 → Aug 2026 overdue | colorectal cancer | Shaukat Khanum Memorial Cancer Hospital & Research Centre | Enrolling by invitation | No outcome recorded |
| — | NCT07010744 | Jul 2025 → Jun 2026 overdue | dyspepsia | Akil Al Islam | Enrolling by invitation | No outcome recorded |
| — | NCT07086937 | Jan → Jun 2025 | Helicobacter pylori infectious disease | Muhammad Aamir Latif | Completed | No outcome recorded |
| — | NCT07836686 | Nov 2024 → Mar 2026 | dental pulp necrosis, pulpitis | Uşak University | Completed | No outcome recorded |
| — | NCT06650540 | Oct 2024 → Oct 2025 overdue | — | Peking University Third Hospital | Not yet recruiting | No outcome recorded |
| — | NCT06434519 | Sep 2024 → Nov 2025 | rosacea | Duke University | Completed | No outcome recorded |
| — | NCT07123792 | Jun 2024 → May 2025 | periodontal disorder | HITEC-Institute of Medical Sciences | Completed | No outcome recorded |
| — | NCT06158451 | Mar → Aug 2024 | periapical periodontitis | Cairo University | Unknown | No outcome recorded |
| — | NCT06907498 | Jan 2024 → Jun 2026 overdue | dientamoebiasis | Sheba Medical Center | Recruiting | No outcome recorded |
| — | NCT05934227 | Jul 2023 → Sep 2024 | periodontitis | Federal University of Minas Gerais | Completed | No outcome recorded |
| — | NCT06305546 | Apr → Oct 2023 | gingivitis | Anam Sattar | Completed | No outcome recorded |
| — | NCT06027151 | Oct 2022 → Jul 2023 | diabetes mellitus, periodontitis | Riphah International University | Completed | No outcome recorded |
| — | NCT05926804 | Aug 2022 → Oct 2026 expected | Helicobacter pylori infectious disease | Miguel O'Ryan Gallardo | Recruiting | No outcome recorded |
| — | NCT05449028 | May 2022 → Dec 2023 | Helicobacter pylori infectious disease | Unidade Local de Saúde de Coimbra, EPE | Unknown | No outcome recorded |
| — | NCT05024188 | Jan → Jul 2022 | — | Assaf Harofeh MC | Unknown | No outcome recorded |
| — | NCT03593252 | Jan 2022 → Jan 2024 | Hirschsprung disease, inflammatory bowel disease, meconium ileus, necrotizing enterocolitis | McMaster University | Unknown | No outcome recorded |
| — | NCT05133193 | Nov 2021 → Jun 2022 | Helicobacter pylori infectious disease | Shandong University | Unknown | No outcome recorded |
| — | NCT05126121 | Nov 2021 → Jun 2022 | Helicobacter pylori infectious disease | Xiuli Zuo | Unknown | No outcome recorded |
| — | NCT05444218 | May 2021 → Jul 2024 | periodontitis | University of Guarulhos | Completed | No outcome recorded |
| — | NCT05946655 | Apr 2021 → Oct 2022 | female infertility, uterine disorder | Jagiellonian University | Completed | No outcome recorded |
| — | NCT04593238 | Nov 2020 → Apr 2021 | — | Cairo University | Unknown | No outcome recorded |
| — | NCT04721704 | Sep 2020 → Sep 2022 | bacterial gastritis | Shaheed Zulfiqar Ali Bhutto Medical University | Unknown | No outcome recorded |
| — | NCT04566211 | Jan 2020 → Sep 2022 | Helicobacter pylori infectious disease | Kaohsiung Veterans General Hospital. | Unknown | No outcome recorded |
| — | NCT04125706 | Nov 2019 → Jul 2020 | periodontitis | Riyadh Elm University | Unknown | No outcome recorded |
| — | NCT03598842 | Jul 2019 → Dec 2025 | helminthiasis, protein-energy malnutrition, tuberculosis | Boston Medical Center | Completed | No outcome recorded |
| — | NCT03917134 | May 2019 → Jan 2020 | abscess, bacterial vaginosis, cellulitis | CES University | Unknown | Missed primary |
| — | NCT03736187 | Apr → Oct 2019 | — | Ain Shams University | Unknown | No outcome recorded |
| — | NCT03856671 | Jan 2019 → Dec 2022 | colorectal cancer | Third Affiliated Hospital, Sun Yat-Sen University | Completed | Met primary |
| — | NCT04006340 | Jan → Aug 2019 | Helicobacter pylori infectious disease | Seoul National University Hospital | Unknown | Missed primary |
| — | NCT03692819 | May 2018 → Aug 2020 | chronic periodontitis | São Paulo State University | Completed | No outcome recorded |
| — | NCT03572777 | Apr 2018 → Oct 2019 | Helicobacter pylori infectious disease | Antonio Mestrovic | Completed | No outcome recorded |
| — | NCT03436719 | Nov 2017 → Jul 2020 | rectal cancer | State Scientific Centre of Coloproctology, Russian Federation | Unknown | No outcome recorded |
| — | NCT03365609 | Sep 2017 → Oct 2025 overdue | Helicobacter pylori infectious disease | Ying HUANG | Recruiting | No outcome recorded |
| — | NCT05581706 | Sep 2017 → Feb 2020 | — | Ege University | Completed | Mixed |
| — | NCT03234296 | Aug 2017 → Sep 2020 overdue | appendicitis | Turku University Hospital | Enrolling by invitation | Missed primary |
| — | NCT04051255 | Mar 2017 → Mar 2020 | periodontitis, aggressive | University of Campinas, Brazil | Unknown | No outcome recorded |
| — | NCT02916134 | Sep 2016 → Dec 2019 | appendicitis | Beaumont Hospital | Completed | No outcome recorded |
| — | NCT02689583 | Mar 2016 → Mar 2017 | gastric ulcer, gastritis | First Affiliated Hospital of Zhejiang University | Unknown | No outcome recorded |
| — | NCT03069976 | Jan 2016 → Aug 2021 | autoimmune hepatitis, primary sclerosing cholangitis | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | Completed | No outcome recorded |
| — | NCT02646332 | Dec 2015 → Jul 2020 | Helicobacter pylori infectious disease | Kaohsiung Veterans General Hospital. | Completed | No outcome recorded |
| — | NCT02459665 | Jun 2015 → Feb 2016 | bacterial vaginosis | Janneke van de Wijgert | Completed | No outcome recorded |
| — | NCT02154061 | Apr 2015 → May 2017 | influenza | Emory University | Completed | No outcome recorded |
| — | NCT02404064 | Mar 2015 | appendicitis | HaEmek Medical Center, Israel | Unknown | No outcome recorded |
| — | NCT05655338 | Jan 2015 → Jun 2016 | periodontitis, aggressive | University of Ljubljana | Completed | No outcome recorded |
| — | NCT02217722 | Oct 2014 → Dec 2015 | ulcerative colitis | Prof. Arie Levine | Terminated | No outcome recorded |
| — | NCT02189668 | Jul 2014 → Jul 2015 | appendicitis | Peter Minneci | Terminated | Missed primary |
| — | NCT02127749 | Jun 2014 → Dec 2015 | — | Academic Medical Center - University of Amsterdam | Completed | Missed primary |
| — | NCT02033408 | Jan 2014 → Dec 2018 | Crohn's colitis, ulcerative colitis | Shaare Zedek Medical Center | Completed | Met primary |
| — | NCT01718912 | Nov 2013 → Sep 2014 | periodontal disorder | Oravital Inc | Completed | No outcome recorded |
| — | NCT02596620 | Oct 2013 → Oct 2015 | Helicobacter pylori infectious disease | Chang Gung Memorial Hospital | Completed | No outcome recorded |
| — | NCT02541864 | Jul 2013 → Aug 2015 | Helicobacter pylori infectious disease | Kaohsiung Veterans General Hospital. | Completed | No outcome recorded |
| — | NCT02196740 | Jun 2013 → Dec 2014 | periapical periodontitis | Lin Jiacheng | Unknown | No outcome recorded |
| — | NCT02340182 | Mar → Sep 2013 | infectious disease with sepsis | W.J. Wiersinga, MD, PhD | Completed | No outcome recorded |
| — | NCT01722708 | Nov 2012 → Jul 2025 | bacterial vaginosis | HaEmek Medical Center, Israel | Completed | No outcome recorded |
| — | NCT02359435 | Oct 2012 → Feb 2015 | Helicobacter pylori infectious disease | Kaohsiung Veterans General Hospital. | Completed | No outcome recorded |
| — | NCT03880448 | Sep 2012 → Jan 2018 | chronic periodontitis | Universidad Complutense de Madrid | Completed | No outcome recorded |
| — | NCT01568944 | Mar 2012 → Sep 2014 | chronic periodontitis | Augusta University | Completed | No outcome recorded |
| — | NCT01572558 | Feb → Oct 2012 | appendicitis | Karolinska University Hospital | Completed | No outcome recorded |
| — | NCT06177119 | Jan → Jul 2012 | periodontitis | Belén Retamal-Valdes | Unknown | No outcome recorded |
| — | NCT01420367 | Nov 2011 → Nov 2013 | appendicitis | Monash University | Completed | No outcome recorded |
| — | NCT01760824 | May 2011 → Oct 2012 | Helicobacter pylori infectious disease | The University of Hong Kong | Completed | Missed primary |
| — | NCT01347632 | Apr → Dec 2011 | bacterial vaginosis, vaginal discharge | CONRAD | Completed | No outcome recorded |
| — | NCT01194115 | Sep 2010 → Sep 2012 | — | University of Cincinnati | Unknown | Met primary |
| — | NCT01168063 | Feb 2010 → Mar 2012 | Helicobacter pylori infectious disease | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| — | NCT02349685 | Jan 2010 → Jun 2014 | Helicobacter pylori infectious disease | Seoul National University Bundang Hospital | Completed | No outcome recorded |
| — | NCT01022567 | Nov 2009 → Jun 2012 | appendicitis | Turku University Hospital | Unknown | Missed primary |
| — | NCT01405365 | Aug 2009 → Dec 2011 | obesity disorder, periodontitis | Federal University of Rio Grande do Sul | Unknown | No outcome recorded |
| — | NCT00589329 | Dec 2007 → Oct 2012 | — | MetroHealth Medical Center | Terminated | No outcome recorded |
| — | NCT01547559 | Jun 2007 → Nov 2014 | drug allergy | Sun Yat-sen University | Unknown | No outcome recorded |
| — | NCT00355602 | Jul 2006 → Dec 2008 | ulcerative colitis | University of Dundee | Completed | No outcome recorded |
| — | NCT00456729 | May → Jul 2006 | disorder of iron metabolism and transport, malabsorption syndrome | HaEmek Medical Center, Israel | Completed | No outcome recorded |
| — | NCT00713999 | Aug 2001 → Apr 2002 | sexually transmitted disease, urinary schistosomiasis | University of Aarhus | Completed | No outcome recorded |
| Comparator or background therapy298 trials | ||||||
| Phase 0 | NCT06640439 Background | Oct 2024 → Feb 2025 overdue | impacted teeth, multiple | Huashan Hospital | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT05829109 Background | Sep 2024 → Dec 2026 expected | pouchitis | Maia Kayal | Recruiting | No outcome recorded |
| Phase 0 | NCT06135974 Background | Feb → Dec 2024 | bacterial vaginosis | Massachusetts General Hospital | Completed | No outcome recorded |
| Phase 0 | NCT04968951 Comparator | Nov 2021 → Aug 2022 | ulcerative colitis | Ari M Grinspan | Terminated | No outcome recorded Stop: Business |
| Phase 0 | NCT03042091 Background | Sep 2016 → Oct 2020 | colorectal neoplasm, diverticulitis, inflammatory bowel disease | Thomas Jefferson University | Unknown | No outcome recorded |
| Show all 298 trials opens the full record — a long page | ||||||
News releases announcing trial results or a regulatory action · 25
| Date | Issuer | Release |
|---|---|---|
| 2025-06-18 | Saptalis Pharmaceuticals LLC | Regulatory Saptalis Pharmaceuticals Launches Fluoxetine Oral Solution, USP 20 mg/5 mL saptalis.com ↗
Saptalis Pharmaceuticals, LLC is pleased to announce that the U.S. Food and Drug Administration (FDA) has approved its Abbreviated New Drug Application (ANDA) for Metronidazole Vaginal Gel, 0.75%. |
| 2025-02-07 | AbbVie | Regulatory U.S. FDA Approves EMBLAVEO™ (aztreonam and avibactam) for the Treatment of Adults With Complicated Intra-Abdominal Infections With Limited or No Treatment Options abbvie.com ↗
It is approved in combination with metronidazole, for patients 18 years and older who have limited or no alternative options for the treatment of complicated intra-abdominal infections (cIAI), including those caused by the following susceptible Gram-negative microorganisms: Escherichia coli , Klebsiella pneumoniae , Klebsiella oxytoca , Enterobacter cloacae complex , Citrobacter freundii complex , and Serratia marcescens . |
| 2024-12-31 | Saptalis Pharmaceuticals LLC | Regulatory Saptalis Announces FDA Approval of Metronidazole Vaginal Gel, 0.75% saptalis.com ↗
Saptalis Pharmaceuticals, LLC is pleased to announce that the U.S. Food and Drug Administration (FDA) has approved its Abbreviated New Drug Application (ANDA) for Metronidazole Vaginal Gel, 0.75%. |
| 2023-11-13 | Saptalis Pharmaceuticals LLC | Regulatory Saptalis Announces FDA Approval and Commercial Launch of LIKMEZTM (Metronidazole Oral Suspension) saptalis.com ↗
Saptalis Pharmaceuticals, LLC is pleased to announce the FDA approval of its New Drug Application of Metronidazole Oral Suspension 500mg/5mL, submitted pursuant to section (505) (b) (2) and commercial launch of the product under the brand name LIKMEZ™. |
| 2023-09-25 | Appili Therapeutics Inc. | Regulatory Appili Therapeutics Announces U.S. FDA Approval of LIKMEZ™ (ATI-1501) Metronidazole Oral Suspension appilitherapeutics.com ↗
today announced that its manufacturing and commercialization partner, Saptalis Pharmaceuticals, LLC (“Saptalis”) received approval from the U.S. Food and Drug Administration (“FDA”) for Metronidazole Oral Suspension 500mg/5mL (ATI-1501). |
| 2023-07-27 | Cosette Pharmaceuticals, Inc. | Regulatory Cosette Pharmaceuticals Launches Metronidazole Vaginal Gel 0.75%, AB-rated to MetroGel-Vaginal® 0.75% cosettepharma.com ↗
Cosette Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved its abbreviated new drug application (ANDA) for a generic version of MetroGel-Vaginal® (metronidazole vaginal gel 0.75%) by Bausch Health US, LLC. |
| 2022-01-28 | Glenmark Pharmaceuticals Ltd. India | Regulatory Glenmark Pharmaceuticals receives ANDA approval for Metronidazole Vaginal Gel, 0.75% glenmarkpharma.com ↗
Glenmark Pharmaceuticals Inc., USA (Glenmark) has received final approval by the United States Food & Drug Administration (U.S. FDA) for Metronidazole Vaginal Gel, 0.75%, the generic version of MetroGel-Vaginal®1 Gel, 0.75%, of Bausch Health US, LLC. |
| 2021-09-01 | Alembic Pharmaceuticals Ltd. | Regulatory Press Release Aleor USFDA Final Approval Metronidazole Gel USP. 1%. alembicpharmaceuticals.com ↗
Alembic Pharmaceuticals Limited (Alembic) today announced that its joint venture Aleor Dermaceuticals Limited (Aleor) has received final approvai from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Metronidazole Gel USP, 1 %. |
| 2021-05-01 | Alembic Pharmaceuticals Ltd. | Regulatory 4th May, 2021, Vadodara, India alembicpharmaceuticals.com ↗
Alembic Pharmaceuticals Limited (Alembic) today announced that its joint venture Aleor Dermaceuticals Limited (Aleor) has received tentative approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Metronidazole Gel USP, 1 %. |
| 2019-07-03 | Perrigo Company | Regulatory Perrigo Announces FDA Final Approval and Launch Of The AB-rated Generic Version Of Metrogel-Vaginal® Gel perrigo.com ↗
Perrigo Company plc (NYSE; TASE: PRGO) today announced its product development partner received final approval from the U.S. Food and Drug Administration for its AB-rated Abbreviated New Drug Application ("ANDA") referencing Metrogel-Vaginal ® (metronidazole vaginal gel 0.75%). |
| 2018-07-30 | Appili Therapeutics Inc. | Results Appili Therapeutics Completes Phase 1 Study for ATI-1501, Its Taste-Masked Oral Metronidazole Suspension appilitherapeutics.com ↗
The clinical study results announced today showed that a single 500 mg dose of ATI-1501 achieved equivalent systemic drug levels to a 500 mg metronidazole tablet under fasted and fed conditions. |
| 2017-09-13 | Lupin Limited | Regulatory Lupin receives FDA approval for generic Flagyl® Tablets lupin.com ↗ |
| 2016-02-26 | Takeda | Regulatory Takeda Obtains New Drug Application Approval for Helicobacter pylori [※] Eradication triple-drug Blister Packs Containing TAKECAB tablet, "VONOSAP ® pack 400", "VONOSAP ® pack 800" and "VONOPION ® pack" in Japan takeda.com ↗
Approval was also received for “VONOPION ® pack”, a triple-drug blister pack containing “TAKECAB ® tablet” for secondary eradication of H. pylori . |
| 2015-03-26 | Takeda | Regulatory New Drug Application for a Single Pack Containing TAKECAB for Eradication of Helicobacter pylori in Japan takeda.com ↗ |
| 2015-03-26 | Otsuka Pharmaceutical Development & Commercialization, Inc. | Regulatory New Drug Application for a Single Pack Containing TAKECAB for Eradication of Helicobacter pylori in Japan otsuka.co.jp ↗
Takeda has submitted an application for a single pack for the first eradication of Helicobacter pylori. |
| 2013-08-21 | Eisai Inc. | Regulatory EISAI RECEIVES APPROVAL TO MARKET PARIET® TRIPLE FORMULATION PACKS RABECURE® 400 AND 800 AND RABEFINE®, FOR PRIMARY AND SECONDARY H. PYLORI ERADICATION RESPECTIVELY, IN JAPAN eisai.com ↗ |
| 2013-02-21 | Tanabe Pharma Corporation | Regulatory Helicobacter pylori Gastritis Approved as Additional Indication in Japan for Helicobacter pylori Eradication by Triple Therapy with Proton Pump Inhibitor tanabe-pharma.com ↗
Helicobacter pylori Gastritis Approved as Additional Indication in Japan for Helicobacter pylori Eradication by Triple Therapy with Proton Pump Inhibitor |
| 2013-02-21 | Kyowa Kirin, Inc. | Regulatory Pasetocin® and Sawacillin®: Approval for Additional Indication for Helicobacter pylori Eradication by Triple Therapy with Proton Pump Inhibitors and either Clarithromycin or Metronidazole kyowakirin.com ↗
has been approved by Japan's Ministry of Health, Labour and Welfare. |
| 2013-02-21 | Eisai Inc. | Regulatory Helicobacter pylori Gastritis Approved as Additional Indication in Japan for Helicobacter pylori Eradication by Triple Therapy with Proton Pump Inhibitor eisai.com ↗ |
| 2012-08-31 | Tanabe Pharma Corporation | Regulatory Companies Submit Joint Application Seeking Approval for Additional Indication for Helicobacter pylori Eradication by Concomitant Therapy with Proton Pump Inhibitors, Amoxicillin Hydrate and either Clarithromycin or Metronidazole tanabe-pharma.com ↗
Companies Submit Joint Application Seeking Approval for Additional Indication for Helicobacter pylori Eradication by Concomitant Therapy with Proton Pump Inhibitors, Amoxicillin Hydrate and either Clarithromycin or Metronidazole |
| 2012-08-31 | Eisai Inc. | Regulatory Companies Submit Joint Application Seeking Approval for Additional Indication for Helicobacter pylori Eradication by Concomitant Therapy with Proton Pump Inhibitors, Amoxicillin Hydrate and either Clarithromycin or Metronidazole eisai.com ↗
they have submitted a joint application * to Japan’s Ministry of Health, Labour and Welfare seeking approval of Helicobacter pylori (“ H. pylori ”) gastritis as an additional indication |
| 2012-05-31 | Eisai Inc. | Regulatory EISAI SEEKS APPROVAL TO MARKET PARIET® TRIPLE FORMULATION PACK IN JAPAN FOR HELICOBACTER PYLORI ERADICATION eisai.com ↗
announced today that it has submitted a marketing authorization application to Japan’s Ministry of Health, Labour and Welfare seeking approval for two types of new triple formulation packs |
| 2010-06-18 | Tanabe Pharma Corporation | Regulatory Approval of Additional Indications for Helicobacter pylori Eradication by Concomitant Therapy with Proton Pump Inhibitors tanabe-pharma.com ↗
they have received approval from the Japanese Ministry of Health, Labor and Welfare for additional indications for Helicobacter pylori (“H. pylori”) eradication by concomitant therapy |
| 2010-06-18 | Eisai Inc. | Regulatory Approval of Additional Indications for Helicobacter pylori Eradication by Concomitant Therapy with Proton Pump Inhibitors eisai.com ↗ |
| 2009-10-01 | Eisai Inc. | Regulatory Application Submitted for Additional Indications for Helicobacter pylori Eradication by Concomitant Therapy with Proton Pump Inhibitors eisai.com ↗ |
All press releases naming this drug 29 releases
Evidence & citations 33 cited values
Every value below carries the sentence it was read from. 624 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | metronidazole | “in patients who failed a first line treatment , or to treatment guided by the molecular test: PPI , amoxicillin 1g, clarithromycin 500 mg X 2 /day for 7 days in case of...” NCT01168063 ↗596“14-day bismuth quadruple therapy (pantoprazole, bismuth subcitrate, tetracycline, and metronidazole for 14 days) or 14-day hybrid therapy (a 7-day dual therapy with...” PMID 28807915 ↗ Oct 2017 “Bacterial or Viral infection treatment may include: Doxycycline, Minocycline, Nitazoxanide, Hydroxychloroquine, Rifampin, Dapsone, Azithromycin, Tetracycline, Benzathine...” NCT05894954 ↗ “The medical intervention consists of intravenous dexamethasone (10 mg if bodyweight \< 70 kilograms, 20 mg if bodyweight \> 70 kilograms), intravenous cefazolin 2 grams,...” NCT04998513 ↗ “A is amoxicillin (1000 mg thrice daily), B is colloidal bismuth subcitrate (120 mg thrice daily), M is metronidazole (500 mg thrice daily), P is a proton pump inhibitor, i.e.,...” NCT06687473 ↗ “Sequential therapy comprised esomeprazole (40 mg) or tegoprazan (50 mg) plus amoxicillin (1000 mg) twice daily for the initial 5 days, followed by esomeprazole (40 mg) or...” PMID 39434634 ↗ Sep 2024 “Based on the susceptibility results and penicillin-allergic test, a tailored 7-day triple or quadruple therapy regimen is prescribed, including Tegoprazan , Amoxicillin,...” NCT07405697 ↗ “Group 1: (110) participants received reverse hybrid regimen in the form of clarithromycin 500mg bid, omeprazole 20 mg bid, amoxicillin 1gm bid, and metronidazole 500 mg tid for...” NCT04039412 ↗ “In case of allergy to Amoxicillin-clavulanate: intravenous administration ciprofloxacin 2 times a day 400 mg and metronidazole 3 times a day 500 mg. In case of oral...” NCT01111253 ↗ “esomeprazole 20 mg plus amoxicillin 1 g, twice daily for 5 days, then esomeprazole 20 mg with clarithromycin 500 mg and metronidazole 500 mg, twice daily for another 5...” NCT01547559 ↗ “Fourteen-day esomeprazole, tripotassium dicitrate bismuthate, metronidazole and tetracycline (EBMT) therapy or esomeprazole, moxifloxacin and amoxicillin (MEA) therapy was...” PMID 26452405 ↗ Oct 2015 |
| Known as | anaerobic gel | “0.8 % Metronidazole gel (anaerobic gel)” NCT03142607 ↗ |
| Known as | Antibiotics, Metronidazole, Flagyl | “Antibiotics, Metronidazole, Flagyl®” NCT03897244 ↗ |
| Known as | Flagyl | “These products are: Metronidazole benzoate (400 mg metronidazole per sachet oral granules)/Terix Labs Ltd, Test product manufactured by ONE PHARMA, Greece and Flagyl™ 400 mg...” NCT02402283 ↗25“Chemotherapeutic agents used are metronidazole tablets 500 mg (Flagyl®, Sanofi, Egypt), ciprofloxacin tablets 500 mg (Ciprofloxacin tablets USP 39®, European pharmaceuticals,...” NCT06158451 ↗ “Double antibiotic paste (DAP): metronidazole (Flagyl, Sanofi-Aventis, Turkey) and ciprofloxacin (Cipro, Biofarma, Turkey) powdered antibiotics were stored and sealed in...” NCT05581706 ↗ “Patients will be given rectal metronidazole (Flagyl) 500 mg/dose for children weighing 10-14,9 kg, 1000 mg/dose for those weighing 15-29,9 kg and 1500 mg/dose for those...” NCT02942485 ↗ “Intralesional metronidazole (5 mg/ml, 100 ml, Flagyl®, Sanofi, France) will be injected into each lesion based on its size (5 mg/cm2).” NCT06798415 ↗ “Intravenous and oral antibiotics without surgery Piperacillin/Tazobactam and then Augmentin Cipro/Flagyl if Penicillin allergic” NCT02189668 ↗ “Drug: Metronidazole 500 mg, po, twice daily for 7 days (Other Names: Flagyl, Noritate, Rosadan, Vandazole, Flagyl ER, Vitazol)” NCT01731236 ↗ “Versus Immediate Release Metronidazole (Flagyl) in Patients With Mild to Moderate C. Difficile Associated Diarrhea (CDAD)” NCT01559545 ↗ “Each subject will received oral Amoxicillin/Amoxil/lansoprazole/Flagyl 250 mg of each three times a day for 8 days.” NCT01568944 ↗ “Drugs used would be anything from: zosyn, ciprofloxacin or ceftriaxone and flagyl, augmentin” NCT05724628 ↗ “Metronidazole (Flagyl 500 mg tablets; Sanofi Aventis Pharma, Cairo, Egypt)” NCT03533231 ↗ |
| Known as | Flagyl (Metronidazole) | “Flagyl (Metronidazole)” NCT01564823 ↗ |
| Known as | Flagyl (Metronidazole), oral suspension. Sanofi-aventis | “Flagyl® (Metronidazole), oral suspension. Sanofi-aventis” NCT01314976 ↗ |
| Known as | Flagyl ER | “Drug: Metronidazole 500 mg, po, twice daily for 7 days (Other Names: Flagyl, Noritate, Rosadan, Vandazole, Flagyl ER, Vitazol)” NCT01731236 ↗ |
| Known as | flasinyl | “metronidazole, flasinyl® 500mg tid 5 days (D6-D10)” NCT02373280 ↗ |
| Known as | GK567 | “GK567: Metronidazole Gel 0.75%” NCT01541930 ↗ |
| Known as | GK567: Metronidazole Gel 0.75% | “GK567: Metronidazole Gel 0.75%” NCT01541930 ↗ |
| Known as | Likmez | “Likmez® (metronidazole) Oral Suspension” NCT07146217 ↗ |
| Known as | Medazol | “Metronidazole ('Medazol') 500 mg bid for 14 days” NCT03572777 ↗ |
| Known as | MET | “Herein, we aim to evaluate the effectiveness of oral Chinese-origin Lactobacillus with adjuvant metronidazole (MET) on treating Chinese BV patients.” PMID 37575226 ↗ Jul 20234“Metronidazole (MET) is an antibiotic that is particularly effective against Gram negative bacterial species.” NCT00066066 ↗ “Group B: Amoxicillin AMO+ Metronidazole MET+ Proton pump inhibitor PPI” NCT04721704 ↗ “amoxicillin + metronidazole (AMX + MET) versus clarithromycin (CLM)” PMID 31257591 ↗ Jul 2019 “ceftriaxone-metronidazole (CTX/MET)” PMID 22439781 ↗ Mar 2012 |
| Known as | metraonidazoel | “amoxicillin 1000 mg bid ,esomprazole 20 bid for one week then levofloxacine 500 mg q.d, metraonidazoel 500 500 bid, and esomprazole 20 bid for one week” NCT06065267 ↗ |
| Known as | METRO | “two metronidazole (METRO) tablets and one doxycycline hyclate (DOXY) simulant at a time, twice daily for 14 days” PMID 38584600 ↗ Mar 20241“Tetracycline; Metronidazole, METRO, NSC-50364; with Bismuth Subsalicylate; Omeprazole.” NCT00002682 ↗ |
| Known as | Metrogel | “Metronidazole is a nitroimidazole. Metronidazole gel (MetroGel) is applied vaginally 7.5 mg/gm daily for 5 days” NCT02766023 ↗4“MetroGel® (metronidazole gel), 1.0% 1x/day” NCT00249782 ↗ “Metronidazole Topical Gel 1% (Metrogel)” NCT01513863 ↗ “Metronidazole (Metrogel)” NCT00855595 ↗ |
| Known as | Metrogyl | “Metrogyl (Metronidazole Injection IP) J.B.Chemicals & Pharmaceuticals Ltd.” NCT00360607 ↗ |
| Known as | metronidazol | “Meropenem and Metronidazol will be used as intravenous antibiotics, Ciprofloxacin and Metronidazol will be used as oral antibiotics.” NCT01572558 ↗6“Antibiotics for Clostridioides infection (oral vancomycin) or association of intravenous metronidazol for severe cases.” NCT06107569 ↗ “Metronidazol” NCT02099240 ↗ |
| Known as | Metronidazol 500mg (Metronidazole 500mg; B.Braun Melsungen AG, Germany) | “Metronidazol 500mg (Metronidazole 500mg; B.Braun Melsungen AG, Germany)” NCT01524081 ↗ |
| Known as | Metronidazole (Efloran) | “Metronidazole (Efloran)” NCT05655338 ↗ |
| Known as | Metronidazole Hydrochloride | “Drug: Metronidazole Hydrochloride” NCT00002682 ↗ |
| Known as | Metronidazole Vaginal Gel 0.75% | “Metronidazole Vaginal Gel 0.75% is an FDA-approved drug” NCT03091777 ↗ |
| Known as | Metronidazole-Flagyl | “Metronidazole-Flagyl®” NCT02033408 ↗1“Metronidazole: Flagyl” NCT01219764 ↗ |
| Known as | MNZ | “Metronidazole (MNZ)-based re-eradication therapy, such as triple PPI/AMPC/MNZ therapy, also achieved high eradication rates and has been recommended as the second line therapy in Japan.” NCT00197418 ↗1“Although metronidazole (MNZ) has been used worldwide for more than 4 decades” PMID 25442806 ↗ Nov 2014 |
| Known as | MTZ | “The benefits of amoxicillin (AMX) plus metronidazole (MTZ) adjunctive to scaling and root planing (SRP) require further investigation, particularly in individuals with a high...” NCT05934227 ↗10“They will be randomized into one of two arms; metronidazole (MTZ) 2 g single dose (CDC recommended treatment regimen) or MTZ 500 mg twice daily x 7-day dose (CDC alternative...” NCT01832480 ↗ “The authors compared the effect of metronidazole (Mtz) on full-mouth periodontal debridement (PD= 1 hour of ultrasonic calculus/plaque removal) in smokers with CP.” NCT01938183 ↗ “Metronidazole (MTZ) is indicated for the treatment of BV and TV and is also safe to administer in the second and third trimesters of pregnancy” NCT04189744 ↗ “The metronidazole (MTZ) 2-gm single dose (recommended) is as effective as the 7-day 500 mg twice a day dose (alternative)” PMID 21423852 ↗ Dec 2010 “Children in MTZ-based triple regimen received metronidazole, PPI, and clarithromycin for 14 days.” NCT07086937 ↗ “The porous metronidazole (MTZ) loaded matrix was fabricated by the freeze-drying technique.” NCT03791099 ↗ “Metronidazole (MTZ) is considered the drug of choice for the treatment of BV.” NCT02365389 ↗ “AIM: To evaluate the effects of the adjunctive use of metronidazole (MTZ) or” PMID 23016867 ↗ Sep 2012 “combined with systemic metronidazole (MTZ) and amoxicillin (AMX).” PMID 27013640 ↗ Mar 2016 “with or without adjunctive metronidazole (MTZ).” PMID 28796888 ↗ Sep 2017 |
| Known as | Noritate | “Drug: Metronidazole 500 mg, po, twice daily for 7 days (Other Names: Flagyl, Noritate, Rosadan, Vandazole, Flagyl ER, Vitazol)” NCT01731236 ↗ |
| Known as | NSC-50364 | “Tetracycline; Metronidazole, METRO, NSC-50364; with Bismuth Subsalicylate; Omeprazole.” NCT00002682 ↗ |
| Known as | Rosadan | “Drug: Metronidazole 500 mg, po, twice daily for 7 days (Other Names: Flagyl, Noritate, Rosadan, Vandazole, Flagyl ER, Vitazol)” NCT01731236 ↗ |
| Known as | Tricho gel | “Conventional MTZ vaginal gel (Tricho gel 0.8%, Sedico, Egypt) twice daily for 5 days” NCT02365389 ↗ |
| Known as | Vandazole | “Drug: Metronidazole 500 mg, po, twice daily for 7 days (Other Names: Flagyl, Noritate, Rosadan, Vandazole, Flagyl ER, Vitazol)” NCT01731236 ↗ |
| Known as | Vitazol | “Drug: Metronidazole 500 mg, po, twice daily for 7 days (Other Names: Flagyl, Noritate, Rosadan, Vandazole, Flagyl ER, Vitazol)” NCT01731236 ↗ |
| Modality | Small molecule | “Metronidazole is a nitroimidazole.” NCT02766023 ↗ |
| Route | Oral | “oral metronidazole tid on days 4-10” NCT00003151 ↗ |